ADAMTS13

From Wikipedia, the free encyclopedia

ADAM metallopeptidase with thrombospondin type 1 motif, 13
Identifiers
Symbol(s)	ADAMTS13 C9orf8
Entrez	11093
OMIM	604134
RefSeq	NM_139025
UniProt	Q76LX8
Other data
Locus	Chr. 9 q34

ADAMTS13 (A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, member 13) is a zinc-containing metalloprotease enzyme that cleaves von Willebrand factor (vWf), a large protein involved in blood clotting. It is also known as von Willebrand factor-cleaving protease (VWFCP). It is secreted in blood and degrades large vWf multimers, decreasing their activity.

1 Genetics
2 Discovery and function
3 Proteomics
4 Role in disease
5 See also
6 Sources
7 External link

[edit] Genetics

The ADAMTS13 gene maps to the ninth chromosome (9q34).

[edit] Discovery and function

Since 1982 it had been known that thrombotic thrombocytopenic purpura (TTP), one of the microangiopathic hemolytic anemias (see below), was characterised in its familial form by the presence in plasma of unusually large von Willebrand factor multimers (ULVWF).

In 1994, VWF was shown to be cleaved between a tyrosine at position 1605 and a methionine at 1606 by a plasma metalloprotease when it was exposed to high levels of shear stress. In 1996, two research groups independently further characterized the enzyme that cleaved VWF. In the next two years, the same two groups showed that the congenital deficiency of vWf-cleaving protease was associated with formation of platelet microthrombi in the small blood vessels. In addition, they reported that in majority of patients IgG antibodies, directed against this enzyme, caused TTP in non-familial cases.

[edit] Proteomics

Genomically, ADAMTS13 shares many properties with the 19 member ADAMTS family, all of which are characterised by a protease domain (the part that performs the protein hydrolysis), an adjacent disintegrin domain and one or more thrombospondin domains. ADAMTS13 in fact has eight thrombospondin domains. It has no hydrophobic transmembrane domain, and hence it not anchored in the cell membrane.

[edit] Role in disease

Deficiency of ADAMTS13 was originally discovered in Upshaw-Shulman syndrome, the recurring familial form of TTP. By that time it was already suspected that TTP occurred in the autoimmune form as well, owing to its response to plasmapheresis and characterisation of IgG inhibitors. Since the discovery of ADAMTS13, specific epitopes on its surface have been shown to be the target of inhibitory antibodies.

Especially since the link between aortic valve stenosis and angiodysplasia was proven to be due to high shear stress (Heyde's syndrome), it has been accepted that increased exposure of vWf to ADAMTS13 due to various reasons would predispose to bleeding by causing increased degradation of vWf. This phenomenon is characterised by a form of von Willebrand disease (type 2a).

[edit] See also

ADAMTS5

[edit] Sources

Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001;14:437-54. PMID 11686108.
Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003;14:1072-81. PMID 12660343.
Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005;106:11-7. PMID 15774620.